Business

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

CNBC · 1h ago Oct 20, 2026

Low-angle view of modern skyscrapers with glass facades in an urban setting, showcasing contemporary architecture.

Photo: Masood Aslami / Pexels

Reported by CNBC.

Read the full story at CNBC

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

More in Business

FTC Moves to Block PlayPower’s Purchase of Rival Playground Maker

Inside the Family Business Succession Problem No One Wants to Talk About

FTC Takes Legal Action Against Ticket Broker for Circumventing Purchase Limits

FTC Disburses Nearly $10 Million to Walmart Wire‑Transfer Victims